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Abstract
Objective: The presence of autoantibodies with adrenergic and cholinergic activity, capable of triggering neurotransmitter
receptor-mediated effects, has been associated with pathogenesis in T. cruzi-infected hosts. The goal of this study was to
investigate the production of anti-M2 muscarinic receptor autoantibodies (Anti-M2R AAbs) as well as the IFN-c profile in
children at the early stage of Chagas disease, and to examine whether trypanocidal chemotherapy with benznidazole (BZ)
could modify both response patterns.
Methods: This study comprised 30 T. cruzi-infected children (mean age: 13.8 years) and 19 uninfected controls (mean age:
12.7 years). Infected patients were treated with BZ and followed-up. Blood samples collected at diagnosis-T0, end of
treatment-T1, and six months later-T2 were analysed by ELISA for detection of Anti-M2R AAbs and circulating levels of IFN-c.
Results: At T0, anti-M2R AAbs were demonstrated in 56.7% of T. cruzi-infected patients, whereas uninfected controls were
100% negative. The average age of Anti-M2R AAbs
+ patients was higher than that from negative population. Infected
children also displayed significantly stronger serum IFN-c responses than controls. Upon BZ treatment, a significant linear
decreasing trend in Anti-M2R AAb reactivity was recorded throughout the follow-up, with 29.7–88.1% decrease at T2. IFN-c
circulating levels also declined by T2.
Conclusion: Anti-M2R AAbs and IFN-c raise early during chagasic infection in children and are downmodulated by BZ
therapy. These findings reinforce the usefulness of early BZ treatment not only to eliminate the parasite but also to reduce
potentially pathogenic immune responses.
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Introduction
Chagas disease, caused by the protozoan parasite Trypanosoma
cruzi, is one of the worlds leading causes of heart disease [1]. The
disease has two successive phases: an initial acute phase lasting
between 30 and 60 days and a chronic phase. A majority of the
patients that progress to the chronic phase remains clinically
asymptomatic for many years, but around 30% of infected
individuals progress to disease associated with cardiac and/or
digestive disorders [2]. Cardiac manifestations include abnormal-
ities of the intraventricular conduction system, ventricular
arrhythmias, sinus node dysfunction, heart failure, aneurysm,
and enlargement and dysfunction of the heart [3]. Arrhythmias
can be related with cardiomyopathy by itself or with autonomic
nervous system alterations [4]. Heart failure and sudden death are
the most common causes of decease in patients with Chagas
disease [3,5]. Although clinical signs and symptoms appear several
years after infection, pathogenic mechanisms can begin since early
stages. Several hypotheses have been proposed to account for
pathogenesis in chronic T. cruzi infections, including parasite
persistence in the myocardium [6], autoimmunity events [7] and
tissue injury due to exacerbated inflammatory reactions [8].
Among alterations induced by host self response, there are data
supporting autoantibody production, able to interact with b1
adrenergic and muscarinic cholinergic M2 receptors in cardiac
tissue [9], leading to early autonomic dysfunction [10,11]. It has
been suggested that the presence of these antibodies could be due
to molecular mimicry between human b1 adrenergic/M2
muscarinic receptors and C terminal regions of ribosomal proteins
of T. cruzi [12]. Recently, this group also demonstrated direct
binding of antibodies developed by chronic chagasic patients to
the native human b1 adrenergic receptor [13].
Regarding the inflammatory response, several studies have
demonstrated that cytokines participate in the control of infection
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[14]. Lymphocytesas well as mononuclear cells infiltrating the heart
tissue of patients with chagasic cardiomyopathy produce signifi-
cantly more inflammatory cytokines, such as interferon (IFN)-c,
than blood cells from infected asymptomatic individuals [15].
Moreover, the secretion of IFN-c has been correlated with the
severecardiac form of Chagasdisease[16]. Invitro experimentshave
shown that IFN-c may induce profound changes in the cardiomy-
ocyte gene expression program, with potential consequences for
myocardial contractility, electric conduction and rhythm [17].
T. cruzi-infected pediatric patients represent the target popula-
tion for parasiticidal therapy. Benznidazole (BZ) is the main drug
available for the treatment of T. cruzi infections. In addition to the
direct in vivo blocking of parasite growth, BZ-treatment appears to
affect host immune regulation [18]. However, little research has
been carried out to address the prompt consequences of etiological
BZ-treatment on the immune response of children at the early
stage of chronic Chagas disease. In this context, we aimed to
evaluate the M2 muscarinic receptor autoantibodies (Anti-M2R
AAb) response as well as the levels of the proinflammatory
cytokine IFN-c in pediatric patients at the early stage of chronic T.
cruzi infection. In addition, during the follow-up of BZ-treated
patients, we examined whether trypanocidal chemotherapy could
modify the patterns of both antibody and cytokine responses.
Materials and Methods
Ethics statement
The study protocol was approved by the Research and Teaching
Committee and Bioethics Committee of Ricardo Gutie ´rrez Chil-
dren’s Hospital. Written consent was required from patients’ legal
representatives, as well as assent from the patient, as appropriate.
Study population
The prospective follow-up study comprised T. cruzi-infected
patients admitted to the Parasitology and Chagas Service at
Ricardo Gutie ´rrez Children’s Hospital, Buenos Aires, Argentina,
for their diagnosis and treatment. Patients with any of the
following conditions were excluded: (a) concurrent infections other
than T. cruzi infection; (b) autoimmune disease; (c) acute or chronic
inflammatory process; (d) having received previous etiologic
treatment. Age- and sex-matched children seronegative for T.
cruzi were considered as controls. Our study population (infected
patients and uninfected controls) comprised children living in
Buenos Aires City and surrounding areas, with similar socioeco-
nomic status. This region is free of vector and is not endemic for
Chagas disease, therefore the re-infection is not possible.
Diagnosis criteria
Serologic diagnosis of T. cruzi infection was carried out by
indirect hemagglutination (IHA, Lab. Polychaco, Buenos Aires,
Argentina), enzyme-linked immunosorbent assay (ELISA, Wiener,
Rosario, Argentina) and passive particle agglutination test (PPA,
Bayer, Buenos Aires, Argentina).
IHA and PPA antibody titers $16, as well as ELISA positive
values higher than 1.2, were considered reactive. Infants with at
least two positive tests were diagnosed as infected by T. cruzi.
Therapeutic regimen and treatment follow-up
The standard of medical care for T. cruzi-infected children is the
etiological treatment. Consequently, all infected infants were
treated with BZ (RADANILH, Roche, Buenos Aires, Argentina) at
5–8 mg/kg/day in 2 daily oral doses, for 60 days. Since diagnosis
(T0), patients were followed-up by clinical (electrocardiogram-
ECG- and echocardiogram-ECHO) and laboratory (IHA and
ELISA for T. cruzi serology; hemogram, hepatogram, creatinin)
evaluations at 30 days, 60 days (end of treatment, T1) and 6
months after completion of chemotherapy (T2). Additionally,
parasitological response to treatment was monitored by qualitative
polymerase chain reaction (PCR) to detect the presence of T. cruzi
DNA in blood samples [19]. Ethical considerations precluded the
inclusion of an untreated control group in the study taking into
account that immediate administration of benznidazole is crucial
to achieve therapeutic success.
Determination of anti-autonomic neurotransmitter
antibodies
Serum samples obtained at different times (T0, T1 and T2) of
follow-up were stored at 220uC until measuring anti-M2R IgG
autoantibody levels by a commercial ELISA kit according to
manufacturers instructions (Chagacor, Lab. Lemos S.R.L, Buenos
Aires, Argentina).
IFN-c measurements
Individual IFN-c serum levels were quantified by double
sandwich ELISA (OptEIA Kit for IFN-c, BD PharMingen, San
Jose, CA, USA) according to manufacturer’s instructions. Supplied
standards were used to generate a standard curve. The assay
sensitivity was 2 ng/ml.
Statistical analysis
Data are expressed as mean value 6 standard error of the mean
(SEM) or median value (interquartile range). IHA titers were log 2-
transformed before applying the statistical test. ELISA values were
expressed as the ratio (R) between optical densities (OD)
determined for each specimen and cut-off value. To compare
two groups, Student t test or Mann-Whitney test were used. One-
way analysis of variance (ANOVA) followed by the Tukey test or
Friedman test was applied to evaluate changes before and after
treatment. Fisher’s exact test was used to compare between-group
proportions. P values of ,0.05 were considered significant.
Statistical analyses were carried out using the Prisma 4.0 software
(GraphPad, San Diego, CA, USA).
Results
Patients’ characteristics
A total of 30 T. cruzi-infected patients were enrolled in this
study. The mean age was 13.8 years (range, 8–17 years) and
female/male ratio was 1 (15 female vs 15 male). On the admission,
all of them presented positive serology for Chagas disease at least
by 2 conventional assays. Anti-T. cruzi antibody titers measured by
ELISA and IHA tests were 8.860.5 and 6.560.2, respectively. All
children were asymptomatic and without cardiac compromise
(normal ECG and ECHO). Route of infection was transplacental
in 27% of patients, vectorial in 4.5% and undefined in 68.5%.
Maternal origin of congenitally infected children was Argentina in
46% of cases, Bolivia in 46% and Paraguay in 8%. The control
group included 19 uninfected children whose mean age was 12.7
years (range, 7–17 years) and female/male ratio was 1.4 (11 female
vs 8 male). There were no significant differences in the age and sex
distribution between T. cruzi-infected children and uninfected
controls.
Pre-treatment Anti-M2R AAb and IFN-c responses
Children were examined for the presence of serum Anti-M2R
AAb and the results are shown in Figure 1A. AntiM2R AAb
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whereas uninfected controls were 100% negative (p=0.0001). The
R value (mean 6 SEM) in T. cruzi-infected patients was 2.260.4.
The average age of Anti-M2R AAb
+ patients was significantly
higher than that from negative population: 14.660.6 years and
1260.8 years, respectively (p=0.0038). T. cruzi-infected children
also displayed higher serum IFN-c levels compared to uninfected
controls (p=0.015) (Figure 1B).
Modulation of Anti-M2R AAb and IFN-c responses after
BZ therapy
In the course of BZ treatment, ten children withdrew from the
study due to adverse events (n=2), moving to another city (n=4)
or not returning (n=4). Among Anti-M2R AAb
+ children at T0,
we verified a significant (p=0.001) linear decreasing trend in their
autoantibody titers throughout the follow-up (Figure 2A). At T2,
ELISA values were significantly lower (p,0.01) than those
detected at T0, representing a decline ranging between 29.7 and
88.1% of the initial level. No correlation between autoantibody
response and heart dysfunction could be established in pediatric
chagasic patients, as all children presented normal ECG and
ECHO examinations.
Serum concentration of IFN-c was also determined as shown in
Table 1 and Figure 2B. The median value of IFNc at T2 was
significantly lower that that observed at T0 (2.5 pg/ml vs 7.5 pg/
ml, p,0.05). Results for these T0 vs T2 pairs of sera revealed a
drop in IFN-c levels that ranged between 10 and 100% of the
initial value. No significant differences were observed in the
comparison of IFN-c levels at T0 vs T1. We were not able to verify
any significant correlation between Anti-M2R AAb and IFN-c
levels. The decrease in Anti-M2R AAb and IFN-c responses in the
lapse between T0 and T2 was accompanied by the negativization
of PCR for T. cruzi in 94% of chagasic children, showing a rapid
decrease in parasite load after treatment.
Changes in anti-T. cruzi antibody levels after BZ therapy were
also evaluated. However, the analysis of the pairs of sera carried
out at T0 and T2 did not show a statistically significant difference:
ELISA titers were 8.860.5 vs 7.760.7, respectively (p=0.08) and
IHA titers were 6.560.2 vs 6.260.3, respectively (p=0.28). Given
that the ascertainment of resolution of T. cruzi infection is based
upon specific serology reverting to negative, this remaining
antibody reactivity prevented the confirmation of cure of treated
pediatric patients at the end of the 6-month follow-up.
Discussion
Autoantibodies with adrenergic and cholinergic activity,
capable of triggering neurotransmitter receptor-mediated effects,
have been detected in human [20] and murine [21] chagasic sera.
Although further in vivo experiments are necessary to reliably
establish the contribution of these antibodies to T. cruzi-mediated
cardiomyopathy [22], they may promote dysautonomia often
found in chronic Chagas patients [23]. Indeed, this kind of
autoantibodies are observed with higher frequency in adults with
chronic Chagas heart disease than in asymptomatic T. cruzi-
infected individuals, suggesting that self-reactive antibodies could
be used as a premature marker of evolution for Chagas
cardiomyopathy [24–26]. In a preliminary report, we demon-
strated for the first time the induction of Anti-M2R AAb in
pediatric patients at early stages of chronic T. cruzi infection [27].
In addition, a clearly decreasing trend in Anti-M2R AAb reactivity
down to healthy levels, accompanied by negative conversion of T.
cruzi serology, was verified by 18–36 months after trypanocidal
chemotherapy.
In the present work, an extension of our previous study, we
observed a significant reduction in Anti-M2R AAb titers as early
as 6 months after completing BZ treatment. Noticeably, the mean
age of Anti-M2R AAb
+ chagasic children was higher than that
recorded for the negative population, further emphasizing the
need for early trypanocidal therapy in T. cruzi-infected young
individuals. Taken together, our findings indicate that in pediatric
Chagas patients Anti-M2R AAb may be downregulated promptly
upon BZ administration.
In some T. cruzi-infected children, pretreatment Anti-M2R
AAbs levels were similar to those found in uninfected controls.
Whether these patients have better prognosis remains to be
elucidated. On the other hand, a subgroup of infected children
presented high Anti-M2R AAb reactivity with potential patho-
genic consequences. The described association between Anti-M2R
AAb and cardiomyocyte dysfunction could be coupled to a
putative agonistic activity of anti-muscarinic receptor antibodies,
capable of inducing a receptor desensitization phenomenon [28].
It has been reported that adult patients at the early stages of
Chagas disease have circulating Anti-M2R AAb linked to
abnormal modulation of vagal activity [11]. Furthermore,
administration of BZ during the advanced phase of experimental
T. cruzi infection prevented the development of a more severe form
of chronic cardiomyopathy, concomitantly with a decrease in the
cardiac M2R-specific antibody response [21].
We searched for any correlation between anti-cardiac autoan-
tibodies and heart dysfunction in our pediatric population with T.
cruzi infection. In contrast with the findings of another research
group who found a high frequency of early electrocardiographic
alterations in seropositive children from endemic areas [29], we
were unable to detect ECG or ECHO abnormalities. This
discrepancy might be attributed to the size and characteristics of
Figure 1. Anti-M2R AAb and IFN-c profiles in pediatric chagasic patients at T0 and uninfected controls. (A) Distribution of anti-M2R AAb
in sera. The group mean and the standard error of the mean are depicted. Dotted line shows cut-off level of the assay. (B) Circulating levels of IFN-c.
The group mean and the standard error of the mean are depicted. * p=0.015 compared to uninfected controls.
doi:10.1371/journal.pone.0027133.g001
Early Chagas Disease Treatment and Immune Response
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e27133the populations evaluated for each study. Unlike our report, de
Andrade and co-workers [29] examined a large population of
seropositive children from a Chagas-endemic area of central
Brazil, where the probability of reinfection, as well as increased
pathogenicity of infecting strains of T. cruzi prevalent in the zone,
could account for the differences observed in ECG profiles.
Because antibodies that bind to myocardial cholinergic receptors
in patients with Chagas disease have shown to trigger physiolog-
ical, morphological, enzymatic and molecular alterations [30], it is
conceivable that these abnormalities could start from the
beginning of T. cruzi infection even in asymptomatic individuals
with normal ECG and ECHO [26,11].
Clinical and experimental evidences support the involvement of
inflammatory cytokines in the pathogenesis of myocardial
dysfunction. In this regard, IFN-c released by infiltrating
lymphocytes, both systemically and locally, has been shown to
contribute to the impaired cardiac function in the experimental
model of autoimmune myocarditis [31]. We herein evaluated the
impact of BZ therapy on expression of the inflammatory cytokine
IFN-c in T. cruzi-infected children. IFN-c levels were found to be
elevated in T. cruzi-infected pediatric patients before initiation of
BZ treatment. In agreement with our results, previous studies
demonstrated the expression of IFN-c in young chagasic patients
from an endemic region of Paraguay, during the acute and
indeterminate stages of infection [32]. In our study population,
IFN-c levels decreased promptly between the time of diagnosis
and 6 months after BZ treatment. These findings could well be
correlated with the decline in the frequency of peripheral IFN-c-
producing T cells specific for T. cruzi observed as early as 12
months after the administration of BZ to chronically infected
adults [33]. An exacerbate production of IFN-c may favour the
cytolytic effects of lymphocytes during Chagas disease increasing
the chances of myocellular destruction in heart tissue [34].
Consequently, our observations highlight the usefulness of the
immunomodulating ability of BZ therapy in T. cruzi infection,
where a disbalanced inflammatory response becomes detrimental.
Interestingly, IFN-c was also associated with a muscarinic
receptor-mediated decrease in heart contractility [31]. On the
other hand, experimental studies suggested that IFN-c binding to
its specific receptors in the heart may lead to a cholinergic
response by interaction of both receptor systems on the surface of
atrial cells [35]. Our results indicate that treatment with BZ in
the early chronic phase of infection could help prevent the
development of immune mechanisms involved in the genesis of
severe chronic cardiomyopathy, despite the lack of complete
parasite eradication [21]. Although the mechanism by which BZ
modulates the production of Anti-M2R AAb and the expression
of IFN-c is unclear, the immunomodulating influence of BZ has
been widely documented. Parasiticidal chemotherapy proved
capable of modulating phagocyte activation, T-cell profile and
the release of immune response mediators, like nitric oxide and
cytokines [36]. Accordingly, in pediatric patients acutely infected
with T. cruzi, elevated circulating levels of CD8 and IL-2 soluble
receptors were detected, which decrease after receiving BZ
therapy [37]. Whether the impact of BZ treatment on both Anti-
M2R AAb and IFN-c responses is a result of parasite load
reduction or a direct effect of the drug on the immune system, is
still an open question.
The so far accepted criterion of cure for Chagas disease relies on
negative seroconversion of the humoral anti-T. cruzi response after
etiological treatment. Nevertheless, in pediatric patients initiating
therapy at the early chronic stage of infection, negative
seroconversion occurs several years after treatment [38], therefore
requiring long-term follow-up. Our present findings suggest that
the BZ-dependent decline of Anti-M2R AAb and IFN-c levels
might provide a surrogate indicator of early therapeutic success in
T. cruzi-infected children. Further studies on a larger number of
infected individuals are needed to clarify their potential use as
novel biomarkers of disease prognosis for those chagasic patients
who test positive for Anti-M2R AAb and/or IFN-c before the
onset of treatment.
In conclusion, in pediatric patients the Anti-M2R AAb and the
IFN-c responses are elicited early in the course of T. cruzi
infection, and decrease after trypanocidal therapy with BZ, even
though the negative seroconversion of T. cruzi- specific antibodies
is not fully accomplished. These findings reinforce the usefulness
of BZ treatment and encourage further studies to elucidate the
potential use of these immune mediators as biomarkers of disease
prognosis.
Figure 2. Anti-M2R AAb and IFN-c profiles in pediatric chagasic patients before and after BZ treatment. (A) Distribution of anti-M2R
AAb in sera. Each point represents one patient positive for anti-M2R AAb. The group mean and the standard error of the mean are also depicted.
* p=0.001, test for linear trend. # p,0.01, T2 vs T0. (B) Circulating levels of IFN-c. Horizontal lines show median values. * p,0.05, T0 vs T2.
doi:10.1371/journal.pone.0027133.g002
Table 1. Distribution of IFN-c values for T. cruzi-infected and
uninfected children.
Median (pg/ml) P25 P75
Infected
T0 7.5 3 13.5
T1 3 2 5.5
T2 2.5 * 1 8.5
Uninfected 22 8
P25: 25
th percentile. P75: 75
th percentile. * p,0.05, T2 vs T0.
doi:10.1371/journal.pone.0027133.t001
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